Sabine Pinnetti

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Tim Heise, Elke Seewaldt-Becker, Sreeraj Macha et al. · Diabetes Obesity and Metabolism · 2013 · 261 citations

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin

Ele Ferrannini, Andreas Berk, Stefan Hantel et al. · Diabetes Care · 2013 · 218 citations · Full text

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Julio Rosenstock, Leo Seman, Ante Jelaska et al. · Diabetes Obesity and Metabolism · 2013 · 208 citations

A <scp>P</scp> hase <scp>IIb</scp> , randomized, placebo‐controlled study of the <scp>SGLT2</scp> inhibitor empagliflozin in patients with type 2 diabetes

Ele Ferrannini, Leo Seman, Elke Seewaldt-Becker et al. · Diabetes Obesity and Metabolism · 2013 · 177 citations

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

Leo Seman, Sreeraj Macha, Gerhard Nehmiz et al. · Clinical Pharmacology in Drug Development · 2013 · 134 citations

Molecular Pharmacology, Urology, Bi 10773 +15